{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:20:30Z","timestamp":1790000430654,"version":"4.0.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jvacx.2024.100432","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T22:43:36Z","timestamp":1704494616000},"page":"100432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["IFN-\u03b1 armed gE elicits superior immunogenicity compared to unmodified antigens and flagellin armed gE in mice"],"prefix":"10.1016","volume":"17","author":[{"given":"Jiangang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaodan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoke","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongqi","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixue","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jvacx.2024.100432_b0005","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/rmv.362","article-title":"Varicella-zoster virus latency in human ganglia","volume":"12","author":"Kennedy","year":"2002","journal-title":"Rev Med Virol"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100432_b0010","first-page":"1","article-title":"Varicella and herpes zoster: a perspective and overview","volume":"166","author":"Weller","year":"1992","journal-title":"J Infect Dis"},{"issue":"20","key":"10.1016\/j.jvacx.2024.100432_b0015","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","article-title":"Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice","volume":"30","author":"Dendouga","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100432_b0020","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/JVI.02561-12","article-title":"Human anti-varicella-zoster virus (VZV) recombinant monoclonal antibody produced after Zostavax immunization recognizes the gH\/gL complex and neutralizes VZV infection","volume":"87","author":"Birlea","year":"2013","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.jvacx.2024.100432_b0025","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2011-06-363564","article-title":"IFN-\u03b1 enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing","volume":"119","author":"Spadaro","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100432_b0030","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2006.08.008","article-title":"Fifty years of interferon research: aiming at a moving target","volume":"25","author":"Vilcek","year":"2006","journal-title":"Immunity"},{"issue":"20","key":"10.1016\/j.jvacx.2024.100432_b0035","doi-asserted-by":"crossref","first-page":"10542","DOI":"10.1128\/JVI.05441-11","article-title":"A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection","volume":"85","author":"Lu","year":"2011","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.jvacx.2024.100432_b0040","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/s41422-021-00531-8","article-title":"Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2","volume":"31","author":"Sun","year":"2021","journal-title":"Cell Res"},{"issue":"6","key":"10.1016\/j.jvacx.2024.100432_b0045","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1007\/s11033-018-4351-0","article-title":"Construction strategies for developing expression vectors for recombinant monoclonal antibody production in CHO cells","volume":"45","author":"Li","year":"2018","journal-title":"Mol Biol Rep"},{"issue":"14","key":"10.1016\/j.jvacx.2024.100432_b0050","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.1007\/s00253-018-8986-5","article-title":"Efficient mAb production in CHO cells with optimized signal peptide, codon, and UTR","volume":"102","author":"You","year":"2018","journal-title":"Appl Microbiol Biotechnol"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100432_b0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pep.2008.04.013","article-title":"Increasing the homogeneity, stability and activity of human serum albumin and interferon-\u03b12b fusion protein by linker engineering","volume":"61","author":"Zhao","year":"2008","journal-title":"Protein Expr Purif"},{"issue":"10","key":"10.1016\/j.jvacx.2024.100432_b0060","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.addr.2012.09.039","article-title":"Fusion protein linkers: property, design and functionality","volume":"65","author":"Chen","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100432_b0065","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri3806","article-title":"Regulation of antiviral T cell responses by type I interferons","volume":"15","author":"Crouse","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.jvacx.2024.100432_b0070","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1038\/emm.2017.172","article-title":"Bacterial flagellin-a potent immunomodulatory agent","volume":"49","author":"Hajam","year":"2017","journal-title":"Exp Mol Med"},{"issue":"15","key":"10.1016\/j.jvacx.2024.100432_b0075","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.vaccine.2019.02.048","article-title":"Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice","volume":"37","author":"Wui","year":"2019","journal-title":"Vaccine"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224000056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224000056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:11:36Z","timestamp":1762913496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136224000056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":15,"alternative-id":["S2590136224000056"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100432","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IFN-\u03b1 armed gE elicits superior immunogenicity compared to unmodified antigens and flagellin armed gE in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100432"}}